CoQ10 (ubiquinol vs ubiquinone) trials recruiting now
18 registrations that name coQ10 as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 18 registrations
Status
Phase
6US sites across 5 states
1
2 to 4
5 to 19
20 or more
All 18 registrations
RecruitingNCT05422534
CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease
Phase 3
Vanderbilt University Medical Center
About 156 people
Started Jun 1, 2023
In plain words A Phase 3 study of coQ10 in people 18 to 75, run by Vanderbilt University Medical Center. It plans to enroll about 156 people at 2 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: End Stage Renal Disease.
Subjects age 18 to 75 years
On thrice-weekly chronic hemodialysis for at least 6 months (only applicable for patients with ESRD on maintenance hemodialysis).
Clinically stable, adequately dialyzed (single-pool Kt/V >1.2) thrice weekly, for at least 3 consecutive months prior to the study (only applicable for patients with ESRD on maintenance hemodialysis)
The exclusion criteria are on the listing.
What it tests, as registered
CoQ10; Placebo; HB-HIIT; Observational
Registered summary
Frailty and sarcopenia are modifiable risk factors for morbidity and mortality in patients with ESRD. Exercise is the recommended intervention to prevent frailty and sarcopenia, however, many clinical trials have shown limited clinical improvement in muscle mass and physical function. We propose that mitochondrial dysfunction is one of the deterrents to the effectiveness of the exercise. We plan to evaluate the additive effect of HIIT and CoQ10, a mitochondrial-targeted therapy, on mitochondrial function and physical performance. The full summary is on the listing.
Where, as registered
2 US sites in 2 states.
RecruitingNCT06620523
Prevent Cardiac Surgery Associated AKI Trial
Phase 2
George Washington University
About 242 people
Started Jul 18, 2024
In plain words A Phase 2 study of coQ10 in people 18 to 70, run by George Washington University. It plans to enroll about 242 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70. Conditions: Renal Failure; Coronary Artery Disease; Surgery; Surgery-Complications.
Adult 18-70 years of age
Undergoing elective CPB (Cardiopulmonary Bypass) surgery
Baseline GFR (Glomerular Filtration Rate) ≥45 ml/min
The exclusion criteria are on the listing.
What it tests, as registered
CoQ10 1200 mg orally with Glutathione 1000 mg orally; Group B: Placebo CoQ10 orally and Placebo Glutathione orally
Registered summary
Prevent CSA-AKI (Cardiac Surgery Associated Acute Kidney Injury) trial is a double blinded randomized controlled trial, 242 patients undergoing elective cardiopulmonary bypass surgery (CPB)will either receive a placebo or daily 1200 mg of Co enzyme Q10 (CoQ10) and 1000 mg of Glutathione (GSH), the first dose will be given the day before surgery and continues while admitted up to 1 week. Blood and urine samples will be collected. Adverse events related to the study drugs will be collected.
Where, as registered
1 US site in 1 state.
RecruitingNCT07760506
The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic Health
No phase
Applied Science & Performance Institute
About 60 people
Starts Sep 18, 2026 (estimated)
In plain words A study of coQ10 in people 50 to 75, run by Applied Science & Performance Institute. It plans to enroll about 60 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 50 to 75; healthy volunteers accepted. Conditions: Healthy Aging; Inflammaging; Metabolic Health; Quercetin; Coenzyme Q10.
Males and females aged 50 to 75 years
Participants who meet the requirements of a sedentary lifestyle. Meaning, subjects who do not meet the World Health Organization's (WHO) minimum activity guidelines, of at least 150 minutes of moderate-intensity activity, or, 75 minutes of…
BMI of > or equal to 25.00kg/m²
Individuals with > or equal to 5 score relative to high risk for prediabetes as defined by the CDC (https://www.cdc.gov/prediabetes/takethetest)
8 more inclusion criteria and the exclusion criteria are on the listing.
The goal of this clinical trial is to learn if Quercefit® or Ubiqsome™ can improve markers of healthy aging, blood sugar control, and heart health in older adults. It will also learn about the safety of these supplements. The main questions it aims to answer are: 1. Do Quercefit® or Ubiqsome™ improve blood sugar, cholesterol, and markers of aging compared to a placebo? 2. What side effects, if any, do participants have while taking these supplements? Researchers will compare Quercefit® (500 mg/day), Ubiqsome™ (300 mg/day), and a placebo (a look-alike capsule with no active ingredient). The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06694727
A Danish Pragmatic Randomized Trial of Nutritional Supplements in Heart Failure
Phase 3
Tor Biering-Sørensen
About 4,044 people
Started Sep 30, 2025
In plain words A Phase 3 study of coQ10 in people 18 and older, run by Tor Biering-Sørensen. It plans to enroll about 4,044 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Heart Failure.
Individuals aged ≥ 18 years.
Registered with a heart failure diagnosis (ICD-10: I50) as a primary discharge diagnosis in The Danish National Patient Registry and at least one claimed prescription of a renin-angiotensin-system inhibitor and a β-blocker within 120 days…
Heart failure is a common and serious condition. Despite rapid advancements in heart failure treatment, the prognosis remains severe. Smaller studies have shown that two simple, safe, and relatively inexpensive nutritional supplements-coenzyme Q10 and selenium-may reduce the risk of complications associated with heart failure. The DANUTRIO-HF trial will investigate whether these supplements can make a difference for individuals with heart failure. The full summary is on the listing.
Where, as registered
No US site; Denmark (1).
RecruitingNCT07234422
The SELEQT-HF (SELEnium and CoQ10 NuTrition for Heart Failure) Study Will Evaluate the Effect of Adding Selenium/and coQ10 on Top of Standard HF Therapy in Patients With HF and Will do so Using a Pragmatic, Registry Based Randomized Controlled Trial in the Netherlands.
Phase 3
Netherlands Heart Institute
About 1,100 people
Started May 4, 2026
In plain words A Phase 3 study of coQ10 in people 18 and older, run by Netherlands Heart Institute. It plans to enroll about 1,100 people at 7 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Heart Failure.
Age >18 years
Outpatients with chronic HF, NYHA II - ambulatory IV
Serum NT-proBNP concentrations >600 pg/mL (71 pmol/L) if in sinus rhythm; >1000pg/mL (118 pmol/L) if in Atrial fibrillation*
The exclusion criteria are on the listing.
What it tests, as registered
Selenium/CoQ10; Matching Placebo (B)
Registered summary
The goal of this clinical trial is to learn whether taking selenium and coenzyme Q10 (CoQ10) can reduce HF related events and deaths related to cardiovascular disease. Researchers will compare selenium-CoQ10 supplements with a placebo to see if the supplements improve heart health and patient outcomes. Participants will: Receive either selenium-CoQ10 or placebo in addition to their usual heart failure treatment Attend standard clinical visits according to routine clinical care. The study will include 1,100 adults with chronic heart failure. The full summary is on the listing.
Where, as registered
No US site; Netherlands (7).
RecruitingNCT04444349
Protective Effect of CoQ10 Against Negative Inflammatory Response and Organ Dysfunction in Cardiovascular Surgery (PANDA V)
No phase
Nanjing Medical University
About 500 people
Started Feb 1, 2021
In plain words A study of coQ10 in people 18 to 90, run by Nanjing Medical University. It plans to enroll about 500 people at 4 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 90. Conditions: Cardiovascular Disease.
Adult men and women
Who receive cardiovascular surgery
Agree to participate in the surgery and sign the informed consent form
The exclusion criteria are on the listing.
What it tests, as registered
Coenzyme Q10; Standard Medical Therapy
Registered summary
Cardiovascular diseases are the leading causes of death and prescription drug use. Research on certain dietary supplements looks promising as a way to help reduce risk factors. Previous studies showed that CoQ10 levels were decreased in cardiovascular patients and worsening of mitochondrial dysfunction was observed. The overall objective of this study is to determine if supplementing with CoQ10 can reduce inflammatory risk factors in adults with cardiac surgery, independent of other dietary or physical activity changes.
Where, as registered
No US site; China (4).
RecruitingNCT06743802
The Effect of Coenzyme Q10 in Preventing Pain After Thoracoscopic Surgery
Phase 4
The Second Affiliated Hospital of Chongqing Medical University
About 264 people
Started Jan 9, 2025
In plain words A Phase 4 study of coQ10 in people 18 to 75, run by The Second Affiliated Hospital of Chongqing Medical University. It plans to enroll about 264 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Postoperative Pain.
Aged 18-75 years;
American Society of Anesthesiology (ASA) physical status classification I-III;
Scheduled for elective lung resection surgery under thoracoscopy;
Voluntarily opting for patient-controlled intravenous analgesia;
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Coenzyme Q10; Placebo
Registered summary
This study aimed to assess the effectiveness of Coenzyme Q10 in preventing both acute and chronic pain following thoracoscopic surgery, with a focus on its potential benefits in reducing the incidence and severity of pain.
Where, as registered
No US site; China (1).
RecruitingNCT06555575
Ubiquinone vs. Ubiquinol Supplementation
Phase 2
Trio Fertility
About 90 people
Started Jan 23, 2025
In plain words A Phase 2 study of coQ10 in female participants 37 to 43, run by Trio Fertility. It plans to enroll about 90 people at 1 site, none in the US.
The objective of this study is to determine if ubiquinol will result in improved reproductive outcomes in older women at a reduced oral dose compared to current standard treatment with ubiquinone.
Where, as registered
No US site; Canada (1).
RecruitingNCT07789106
A Study on Ubiquinol on Fatigue and Muscle Strength in Healthy Adults Taking GLP-1 Agonists
No phase
StudySetGo
About 90 people
Started Sep 1, 2026
In plain words A study of coQ10 in people 30 to 65, run by StudySetGo. It plans to enroll about 90 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 30 to 65. Conditions: Obesity & Overweight; GLP - 1; Fatigue Severity Scale; Ubiquinol; Muscle Contraction.
Age 30-65 years
Body mass index >27kg/m2 and <35 kg/m2
Currently initiating, or has initiated within the preceding 16 weeks of screening, one of the following MHRA-licensed weight management pharmacotherapies: semaglutide 2.4mg (Wegovy®) or tirzepatide (Mounjaro®) prescribed for the indication…
Is physically mobile and able to complete at least one sit to stand movements
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Ubiquinol 100 MG Oral Capsule; Placebo
Registered summary
The goal of this clinical trial is to learn if a daily ubiquinol supplement can reduce fatigue and help maintain muscle strength in adults aged 30-65 who are taking a GLP-1 weight loss medication (Wegovy® or Mounjaro®). Ubiquinol is a form of Coenzyme Q10 (CoQ10), a substance the body makes naturally that plays a key role in energy production. The full summary is on the listing.
Where, as registered
No US site; United Kingdom (1).
RecruitingNCT05984745
Effect of CoQ10 on the Outcome of MAFLD Patients
Phase 2
Ain Shams University
About 60 people
Started Oct 31, 2023
In plain words A Phase 2 study of coQ10 in people 18 to 80, run by Ain Shams University. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Fatty Liver; NAFLD.
Waist circumference (WC) ≥ 102/88 cm for men and women respectively.
HDL cholesterol <40 mg/dl in men and <50 mg/dl in women or on specific drug therapy.
Plasma Triglycerides ≥ 150 mg/dl or on specific drug therapy.
Blood pressure ≥130 and/or ≥ 85 or on specific anti-hypertensive therapy.
7 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Coenzyme Q10 Forte® capsules
Registered summary
So far there has been no universal treatment for MAFLD since it has a complex etiology that involves ethnic, genetic, metabolic and environmental factors. However, therapeutic life changes including: diet, weight loss, and physical activity remain the cornerstone of treatment and is recommended by both American and European associations. The full summary is on the listing.
Where, as registered
No US site; Egypt (1).
RecruitingNCT06856447
The Role of Coenzyme Q10 in the Prophylaxis of Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer
Phase 1
toqa saad mohammed mohammed
About 22 people
Started Jun 1, 2024
In plain words A Phase 1 study of coQ10 in people 18 and older, run by toqa saad mohammed mohammed. It plans to enroll about 22 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older; healthy volunteers accepted. Conditions: Colorectal Cancer.
Patients with histologically confirmed diagnosis of Stage III colorectal cancer.
Patients who will be scheduled to receive modified FOLFOX-6.
Patients with no contraindication to chemotherapy.
Males and females aged ≥ 18 years old.
5 more inclusion criteria and the exclusion criteria are on the listing.
This study aims to evaluate the possible beneficial role of coenzyme Q10 against oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer.
Where, as registered
No US site; Egypt (1).
RecruitingNCT07677826
Effect of Co-enzyme Q10 and Vitamin C Alone or in Combination After a Surgical Gingival Depigmentation
No phase
Al-Azhar University
About 20 people
Started Mar 2, 2026
In plain words A study of coQ10 in people 18 to 45, run by Al-Azhar University. It plans to enroll about 20 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 45; healthy volunteers accepted. Conditions: Depigmentation Treatment; Depigmentation.
Systemically healthy patient of both genders aged from 18-45 years.
Presence of bilateral physiologic gingival pigmentation in the anterior maxillary or mandibular region DOPI grades III-IV only.
This study aims to assess the clinical effectiveness of Co-enzyme Q10 and Vitamin C, applied individually or in combination after surgical gingival depigmentation.
Where, as registered
No US site; Egypt (1).
Not yet recruitingNCT07668284
COQ10 and Vitamin E for Off-Target Radiation Toxicity
Phase 1 and 2
University of Nebraska
About 200 people
Starts Dec 1, 2026 (estimated)
In plain words A Phase 1 and 2 study of coQ10 in people 19 and older, run by University of Nebraska. It plans to enroll about 200 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 19 and older. Conditions: Prostate Cancer; Uterine Cancer; Cervical Cancer; Anal Cancer.
Pathologically confirmed post-prostatectomy prostate, uterine (endometrial and cervical), or anal cancer.
Scheduled for curative-intent, multi-fraction (at least 15 fractions) external-beam radiotherapy +/- chemotherapy at the study site which does not involve re-irradiation to the same field.
Age ≥ 19 years at the time of consent.
Eastern Cooperative Oncology Group Performance Status ≤ 2.
15 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Coenzyme Q10 Cap/Tab; Vitamin E Cap/Tab
Registered summary
The goal of this supportive care study is to learn if high-dose Vitamin E and CoQ10 in combination can reduce the negative sub-acute and chronic side effects of radiation to the pelvis in adults treated for prostate, uterine, cervical, or anal cancer. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07881601
Effects of Ubiquinol and Ubiquinone on Vascular Function in Healthy Adults With Borderline High LDL-Cholesterol
No phase
SF Research Institute, Inc.
About 120 people
Starts Oct 17, 2026 (estimated)
In plain words A study of coQ10 in people 35 to 65, run by SF Research Institute, Inc.. It plans to enroll about 120 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 35 to 65; healthy volunteers accepted. Conditions: Borderline High LDL-cholesterol.
Males aged 35-65 with BMI 18.5-29.9 kg/m².
Post-menopausal females up to age 65 with BMI 18.5-29.9 kg/m².
Generally healthy individuals with mild cardiovascular risk factors, specifically -borderline high LDL-C between 100 and 159 mg/dL.
No current acute or uncontrolled chronic illness.
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Ubiquinol; Ubiquinone; Placebo
Registered summary
This randomized, double-blind, placebo-controlled clinical trial will evaluate the effects of Ubiquinol and Ubiquinone on vascular endothelial function in generally healthy adults with borderline high LDL-cholesterol. Participants will receive Ubiquinol 200 mg/day, Ubiquinone 200 mg/day, or placebo for 8 weeks. The primary outcome is change in flow-mediated dilation (FMD), a measure of vascular endothelial function, assessed at baseline, Week 4, and Week 8. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07260773
The Effects of Coenzyme Q10 Pretreatment on Ovarian Function and Assisted Reproductive Outcomes in Patients With Ovarian Hyporesponsiveness.
No phase
Tang-Du Hospital
About 128 people
Starts Jul 2026 (estimated)
In plain words A study of coQ10 in female participants 20 to 39, run by Tang-Du Hospital. It plans to enroll about 128 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists female participants 20 to 39. Conditions: Ovarian Response.
Individuals seeking IVF-ET fertility treatment;
Meeting the Bologna criteria for the definition of poor ovarian response (POR), specifically:
(1) Meeting 2 of the following 3 criteria:
① Presence of high-risk factors for POR;
5 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Coenzyme Q10; Placebo
Registered summary
This prospective, randomized, double-blind, controlled study will be conducted at Tangdu Hospital, Air Force Medical University. It plans to enroll 128 patients with poor ovarian response for a 2-year study. The primary objective is to investigate the effects of exogenous coenzyme Q10 supplementation as pre-treatment on ovarian function and assisted reproductive clinical outcomes in patients with poor ovarian response. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07841548
Guishen Yijing Granules for Diminished Ovarian Reserve With Kidney Deficiency Syndrome: A Randomized Controlled Trial
Early phase 1
Shi Yun
About 120 people
Starts Sep 22, 2026 (estimated)
In plain words An early phase 1 study of coQ10 in female participants 25 to 45, run by Shi Yun. It plans to enroll about 120 people and lists no sites yet.
This study is a multicenter, stratified block-randomized, double-blind, double-dummy clinical trial designed to evaluate the efficacy and safety of Guishen Yijing Granules in patients with diminished ovarian reserve (DOR) and kidney deficiency syndrome through multidimensional assessment of clinical outcomes before and after treatment. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07772336
MItochondrial Intervention for Resilience in Older Adults With Coenzyme Q10
No phase
University Medical Centre Ljubljana
About 100 people
Starts Sep 2026 (estimated)
In plain words A study of coQ10 in people 65 and older, run by University Medical Centre Ljubljana. It plans to enroll about 100 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 65 and older; healthy volunteers accepted. Conditions: Frailty; Aging; Mitochondria Health; Skin Aging; Mitochondrial Dysfunction.
Age 65 years or older.
Community-dwelling older adult.
Presence of signs of reduced biological resilience or prefrailty, defined by meeting at least one of the following criteria:
Prefrailty according to the Fried frailty phenotype, defined as the presence of 1-2 of the following criteria: unintentional weight loss, self-reported exhaustion, reduced physical activity, slow walking speed, or reduced handgrip…
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Q10Vital® (CoQ10, ubiquinone); Placebo
Registered summary
This randomized, double-blind, placebo-controlled clinical trial will investigate whether 10 weeks of CoQ10 supplementation can improve biological resilience and functional health in community-dwelling adults aged 65 years or older with signs of reduced biological resilience or prefrailty. Participants will be randomly assigned in a 1:1 ratio to receive either 200 mg of CoQ10 daily or matching placebo for 10 weeks. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07748130
CoQ10 Effects on MDM Liver Fat Via FibroTouchI.
No phase
The 95th Hospital of Putian，Putian, Fujian, China
About 30 people
Starts Sep 2026 (estimated)
In plain words A study of coQ10 in people 18 to 70, run by The 95th Hospital of Putian，Putian, Fujian, China. It plans to enroll about 30 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70; healthy volunteers accepted. Conditions: Mitochondrial Diabetes.
Confirmed as a carrier of the mitochondrial DNA m.3243A>G mutation through genetic testing;
Meeting the diagnostic criteria for diabetes (WHO 1999 diagnostic criteria);
Aged between 18 and 70 years;
Willing to participate and having signed the informed consent form.
The exclusion criteria are on the listing.
What it tests, as registered
Coenzyme Q10 (drug); Only undergo baseline assessments without intervention.; Only undergo baseline assessments without intervention.
Registered summary
Mitochondrial diabetes mellitus (MDM) is a rare subtype of diabetes caused by mitochondrial dysfunction, often accompanied by hepatic steatosis. Coenzyme Q10 (CoQ10), a key electron carrier and antioxidant, may improve mitochondrial function and lipid metabolism. This prospective study aims to evaluate the effect of 12-week CoQ10 supplementation (300 mg/day) on liver fat content (assessed by FibroTouch CAP ) in MDM patients with m.3243A\>G mutation. An exploratory case-control design will compare baseline characteristics among MDM patients, type 1 diabetes patients, and healthy controls. The full summary is on the listing.